Understand the source comparison
ACTH(4-7)-PGP vs Alpha-MSH vs Full-Length ACTH: Peptide Comparison
Melanocortin-derived peptides share overlapping receptor targets but differ significantly in selectivity, potency, and safety profiles. Understanding where ACTH(4-7)-PGP fits within this family clarifies its niche. ACTH(4-7)-PGP MC4R, MC5R > MC3R 15–25 min Mic
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Melanocortin-derived peptides share overlapping receptor targets but differ significantly in selectivity, potency, and safety profiles. Understanding where ACTH(4-7)-PGP fits within this family clarifies its niche.
- ACTH(4-7)-PGP
- MC4R, MC5R > MC3R
- 15–25 min
- Microglia modulation, neuroprotection
- None (no MC2R binding)
- Short half-life; limited human data
- Alpha-MSH (α-MSH)
- MC1R, MC3R, MC4R, MC5R
- 8–12 min
- Anti-inflammatory, fever reduction
- Minimal (weak MC2R)
- Rapid degradation; pigmentation side effects
- Full-Length ACTH (1-39)
- MC2R >> MC1R, MC3R, MC4R
- 10–18 min
- Cortisol elevation, HPA axis activation
- Strong (primary function)
- Sustained use causes Cushing's syndrome
- Tetracosactide (ACTH 1-24)
- MC2R >> others
- 12–20 min
- Diagnostic adrenal testing
- Strong (synthetic ACTH analog)
- Not for chronic use; steroidogenic
- NDP-MSH (synthetic α-MSH)
- MC1R, MC4R, MC5R
- 40–60 min
- Neuroprotection, anti-inflammatory
- None
- Experimental; no human trials
- Professional Assessment
- ACTH(4-7)-PGP is the only melanocortin fragment with documented MC2R avoidance, making it the sole candidate for chronic neuroprotective use without endocrine disruption. Alpha-MSH shares anti-inflammatory properties but causes skin darkening via MC1R (melanogenesis). Full-length ACTH and tetracosactide are diagnostic or acute-use compounds only. Chronic administration produces iatrogenic Cushing's syndrome.
- The bottom line: ACTH(4-7)-PGP was engineered to isolate neuroprotection from steroidogenesis. No other melanocortin peptide achieves this separation as cleanly, but that specificity comes at the cost of very short half-life and limited oral bioavailability. Both barriers to clinical translation.